Cara Therapeutics will host a Virtual R&D Day on March 11, 2022


Cara Therapeutics, Inc.

Presentation to highlight pruritus phase 3 programs with oral difelikefalin

STAMFORD, Conn., Feb. 18 12, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), an early-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients with pruritus, today announced announced that the company will host a virtual research and development (R&D) event on Friday, March 11, 2022, from 1:00 p.m. to 2:00 p.m. ET. The presentation will focus on the initiation of phase 3 programs of oral difelikefalin for the treatment of pruritus in patients with atopic dermatitis and chronic renal failure not dependent on dialysis. An interactive Q&A session will follow the presentation.

Presenters will include:

  • Christopher Posner, President and CEO and Director of Cara Therapeutics

  • Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics

  • Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY

  • Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences

A live audio webcast of the presentation and accompanying slides will be accessible under “Events and Presentations” in the News and Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.

About Cara Therapeutic

Cara Therapeutics is a commercial-stage biopharmaceutical company at the forefront of a new treatment paradigm to improve the lives of patients with pruritus. The company’s new KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease in adults on hemodialysis. The Company is developing an oral formulation of difelikefalin and expects to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease. Phase 2 trials of oral difelikefalin are ongoing in patients with primary biliary cholangitis and notalgia paresthetica with moderate to severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and instagram.

MEDIA CONTACT:
Annie Spinette
6 degrees
973-768-2170
[email protected]

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Therapeutic Cara
203-406-3700
[email protected]

Previous Analysts remain optimistic as Shopify (SHOP) stock falls
Next The municipal council will meet on February 22, 2022